Trials / Completed
CompletedNCT03910361
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver diseases
Detailed description
1. Evogliptin 5mg Group: Administration with Evogliptin 5mg and Placebo for 24weeks 2. Pioglitazone 15mg Group: Administration with Pioglitazone 15mg and Placebo for 24weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evogliptin | evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd |
| DRUG | Pioglitazone | pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd |
Timeline
- Start date
- 2019-04-12
- Primary completion
- 2020-07-02
- Completion
- 2020-07-02
- First posted
- 2019-04-10
- Last updated
- 2021-04-29
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03910361. Inclusion in this directory is not an endorsement.